MedPath

Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Role of Anti-platelet in Treatment of Acute Ischemic Stroke

Not Applicable
Conditions
Stroke
Interventions
First Posted Date
2017-08-30
Last Posted Date
2017-08-31
Lead Sponsor
Assiut University
Target Recruit Count
120
Registration Number
NCT03266731

Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol

Phase 4
Conditions
Invitro Fertilization
Interventions
First Posted Date
2017-08-28
Last Posted Date
2017-08-28
Lead Sponsor
Cairo University
Target Recruit Count
120
Registration Number
NCT03263299
Locations
🇪🇬

Kasr Alainy medical school, Cairo, Egypt

Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes

Phase 4
Completed
Conditions
Carotid Atherosclerosis
Type 2 Diabetes Mellitus
Interventions
First Posted Date
2017-08-14
Last Posted Date
2020-04-08
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
50
Registration Number
NCT03248401
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of

Anti-platelet + Pembro for H&N Tumors

Phase 1
Recruiting
Conditions
Head and Neck Cancer
Interventions
First Posted Date
2017-08-10
Last Posted Date
2024-08-01
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
20
Registration Number
NCT03245489
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation

Not Applicable
Withdrawn
Conditions
Foramen Ovale, Patent
Interventions
Drug: Aspirin
Device: Cardiovascular Implantable Device (CIED)
Device: Gore Cardioform Septal Occluder
First Posted Date
2017-07-28
Last Posted Date
2020-03-13
Lead Sponsor
Mayo Clinic
Registration Number
NCT03232450
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Ginkgo Diterpene Lactone Meglumine Injection on Platelet Reactivity in Acute Ischemic Stroke

First Posted Date
2017-07-17
Last Posted Date
2017-07-17
Lead Sponsor
RenJi Hospital
Target Recruit Count
40
Registration Number
NCT03219645

Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects

Phase 4
Completed
Conditions
Hypertension,Essential
Obesity
Interventions
First Posted Date
2017-07-02
Last Posted Date
2017-07-02
Lead Sponsor
Beata Krasinska
Target Recruit Count
82
Registration Number
NCT03206944

A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion

Phase 3
Completed
Conditions
Central Retinal Artery Occlusion
Interventions
Drug: Alteplase
Drug: acetylsalicylic acid
Drug: Placebo Oral Tablet
Drug: placebo IV
First Posted Date
2017-06-23
Last Posted Date
2024-01-24
Lead Sponsor
Nantes University Hospital
Target Recruit Count
70
Registration Number
NCT03197194
Locations
🇫🇷

CHU Rouen, Rouen, France

🇫🇷

Ch Perpignan, Perpignan, France

🇫🇷

CH Annecy Genevois, Annecy, France

and more 14 locations

A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects

Phase 1
Completed
Conditions
Thrombosis
Interventions
Drug: BMS-962212
Other: Placebo
Drug: Aspirin
First Posted Date
2017-06-23
Last Posted Date
2017-07-02
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
691
Registration Number
NCT03197779
Locations
🇺🇸

Wcct Global, Llc, Cypress, California, United States

🇺🇸

California Clinical Trials Medical Group, Glendale, California, United States

🇺🇸

Parexel International - Baltimore Epcu, Baltimore, Maryland, United States

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

Phase 3
Terminated
Conditions
Stroke
Interventions
First Posted Date
2017-06-20
Last Posted Date
2023-06-07
Lead Sponsor
Columbia University
Target Recruit Count
1015
Registration Number
NCT03192215
Locations
🇺🇸

VA Greater Los Angeles - West LA VA Medical Center, Los Angeles, California, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Grady Memorial, Atlanta, Georgia, United States

and more 173 locations
© Copyright 2025. All Rights Reserved by MedPath